Replies to post #203810 on Biotech Values

[DewDiligence]

NVS presents phase-3 data in SPMS:

https://www.novartis.com/news/media-releases/novartis-baf312-reduces-risk-disability-progression-pivotal-phase-iii-study?hootPostID=cfa242079cd3be03006662ed67970b9c

NVS announced three weeks ago that this trial hit its primary endpoint (#msg-124762084).